Petroleum jelly

ApprovedSmall molecule

Johnson & Johnson

Petroleum jelly is one of 53 small molecule programs targeting Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

Seborrheic DermatitisActive, not recruiting

Diabetes MellitusApproved

Active, not recruiting

Seborrheic DermatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

286 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Petroleum jelly

Johnson & Johnson

Approved

1 2

E.-Coli-Nissle

UUniversity of Oulu

Phase 3

1 3

Trulicity

Eli Lilly

Preclinical

2 4

Byetta

AstraZeneca

Preclinical

2 5

Paxil CR

GSK

Preclinical

1 6

Simponi

Johnson & Johnson

Preclinical

1 7

Galvus

Novartis

Preclinical

1 8

NOVOLIN R

Novo Nordisk

Preclinical

1 9

Edarbi

Takeda

Preclinical

1 10

Insulin 320

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetes Mellitus1 trial

Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2

Unknown status·IIndonesia University·Phase 4·NCT03815305·159 enrolled

Staphylococcus Aureus1 trial

Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU

Completed·—·Phase 2·NCT02967432·216 enrolled

Irritation1 trial

A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01494714·30 enrolled

Seborrheic Dermatitis1 trial

Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation

Terminated·AAscension Health·N/A·NCT01315951·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Petroleum jelly. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Petroleum jelly compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Petroleum jelly. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Petroleum jelly

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetes Mellitus1 trial

Staphylococcus Aureus1 trial

Irritation1 trial

Seborrheic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News